– Planned Q2 2022 NDA submission following positive topline data from MOMENTUM clinical trial of momelotinib in symptomatic and anemic myelofibrosis patients – – Financial position significantly strengthened – SAN MATEO, Calif.--(BUSINESS WIRE)-
BOSTON--(BUSINESS WIRE)--Cerveau Technologies, Inc. today announced a research collaboration agreement with Roche Products Limited (Roche), on the use of Cerveau’s [F-18]MK-6240, an investigational imaging agent, in Positron Emission Tomography (PET) sc
MORGANTOWN, Pa.--(BUSINESS WIRE)--#BodiesThatMoveBusiness--Morgan Truck Body has unveiled its latest body innovations with the introduction of an electrified refrigerated concept truck body during Work Truck Week, March 8-11, 2022 in Indianapolis (Booth #
US Diagnostic Business Leaders Ruth Abdulmassih and Dennis Flannelly to Help Guide Kenota WATERLOO, Ontario--(BUSINESS WIRE)--Kenota Health announced today that Ruth Abdulmassih and Dennis Flannelly have joined its Board of Directors. Ruth Abdulmassih i
In vivo, IND enabling evaluations of PolyTope® TATX-03 in animal model show: There were no pharmacokinetic aberrations Injection with TATX-03 is well tolerated - with a significant safety margin and no clinical signs of toxicity Maximum tolerate
GMP certification is a key growth catalyst and element of global supply chain and distribution strategy SASKATOON, Saskatchewan--(BUSINESS WIRE)--ZYUS Life Sciences Inc. ("ZYUS"), a Canadian-based life sciences company leading scientific research and dev
TORONTO--(BUSINESS WIRE)--Biomind Labs Inc. (“Biomind Labs” or the “Company”) (NEO: BMND) (OTC: CRSWF) (FSE: 3XI), a leading biotech company focused on innovation and research on endogenous tryptamines (biomolecules acting as psychoneuroplastogens
IMV’s DPX technology elicits a coordinated anti-tumor immune response involving natural killer cells in both translational and preclinical studies Clinical data from the Company’s basket study in advanced, metastatic bladder cancer will be present
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and dev
TORONTO--(BUSINESS WIRE)--BioConnect is thrilled to announce that our Vice President, Marketing & Alliances, Julia Webb-Twoomey, has been recognized by the Security Industry Association (SIA) Women in Security Forum (WISF), as a Power 100 class of 202
Sign up for one of BAM's newsletter to learn more about bioscience, happenings in Manitoba's bioeconomy, industry conferences, and BAM training events.